The Amino-Terminal Fragment of Pro-Brain Natriuretic Peptide in Plasma as a Biological Marker for Predicting Mortality in CommunityAcquired Pneumonia: A Cohort Study
The mean NT-ProBNP values in the deceased patients were 14,035 ng/L (SD: 19,271) compared to 1,711 ng/L (SD: 3,835) in survivors (p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Aim: Community-acquired pneumonia (CAP) is an infectious disease that causes the highest mortality rates in developed countries.
📊
Key Findings & Data:The primary endpoint of this study was to evaluate the relationship between the plasma concentration of the amino-terminal fragment of pro-brain natriuretic peptide (NT-ProBNP) at the time of CAP diagnosis in a hospital emergency room (HER) and its severity, determined as mortality at 30 days.Materials and Methods: A prospective, observational cohort study was used to determine NT-ProBNP (ng/L) in patients with CAP, with a follow-up over 30 days and analysis of the mortality rate.
💡
Conclusion & Impact:The mean NT-ProBNP values in the deceased patients were 14,035 ng/L (SD: 19,271) compared to 1,711 ng/L (SD: 3,835) in survivors (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Aim: Community-acquired pneumonia (CAP) is an infectious disease that causes the highest mortality rates in developed countries. The primary endpoint of this study was to evaluate the relationship between the plasma concentration of the amino-terminal fragment of pro-brain natriuretic peptide (NT-ProBNP) at the time of CAP diagnosis in a hospital emergency room (HER) and its severity, determined as mortality at 30 days.Materials and Methods: A prospective, observational cohort study was used to determine NT-ProBNP (ng/L) in patients with CAP, with a follow-up over 30 days and analysis of the mortality rate. Results: A total of 338 patients were assessed. Thirty patients died within the first 30 days (10.5%). The mean NT-ProBNP values in the deceased patients were 14,035 ng/L (SD: 19,271) compared to 1,711 ng/L (SD: 3,835) in survivors (p
🔖
Cite This Article
TAZÓN-VARELA, M. A., ALONSO-VALLE, H., COLOMO-MÁRMOL, L. F., GALLO-TERÁN, J., PÉREZ-MİER, L. A., MUÑOZ-CACHO, P. (2022). The Amino-Terminal Fragment of Pro-Brain Natriuretic Peptide in Plasma as a Biological Marker for Predicting Mortality in CommunityAcquired Pneumonia: A Cohort Study. Eurasian Journal of Emergency Medicine, Cilt: 15 - Sayı: 1, 30–38. https://ajindex.com/articles/508115
Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50. [CrossRef] Lim WS, Van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community-acquired pneumonia severity on presenta- tion to hospital: an international derivation and validation study. Thorax 2003; 58: 377-82. [CrossRef] Aujesky D, McCausland JB, Whittle J, Scott D, Yealy DM, Fine JM. Reasons why emergency department providers do not rely on the pneumonia severity index to determine the initial site of treatment for patients with pneumonia. Clin Infect Dis 2009; 49: e100-8. Jeong KY, Kim K, Kim TY, Lee CC, Jo SO, Rhee JE, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in hospitalised patients with com- munity-acquired pneumonia. Emerg Med J 2011; 28: 122-7. [CrossRef] Nowak A, Breidthardt T, Christ-Crain H, Bingisser R, Meune C, Tanglay Y, et al. Direct comparison of three natriuretic peptides for prediction of short and long-term mortality in community-acquired pneumonia. Chest 2012; 141: 974-82. [CrossRef] Chang CL, Mills GD, Karalus NC, Jennings LC, Laing R, Murdoch DR, et al. Biomarkers of cardiac dysfunction and mortality from community-ac- quired pneumonia in adults. PLoS One 2013; 8: e62612. Lin SC, Tsai YJ, Huang CT, Kuo YW, Ruan SY, Chuang YC, et al. Prognos- tic value of plasma N-terminal pro B-type natriuretic peptide levels in pneumonia patients requiring intensive care unit admission. Respirolo- gy 2013; 18: 933-41. [CrossRef] Xiao K, Su LX, Han BC, Yan P, Yuan N, Deng J, et al. Analysis of the severity and prognosis assessment of aged patients with community-acquired pneumonia: a retrospective study. Thorac Dis 2013; 5: 626-33. Tazón-Varela M, Alonso-Valle H, Muñoz-Cacho P, Colomo-Mármol LF, Gallo-Terán J, Hernández-Herrero M. N-terminal fragment of pro-brain natriuretic peptide plasma concentration: a new predictive biomarker for community acquired pneumonia? Emergencias 2014; 26: 94-100. WHO. The top 10 causes of death. Geneva: World Health Organization, 2013 Available at: http://www.who.int/mediacentre/factsheets/fs310/ en/index.html Wunderink RG, Waterer GW. Community-acquired pneumonia. N Engl J Med 2014; 370: 6. Brueckmann M, Huhle G, Lang S, Haase KK, Bertsch T, Weiss C, et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005; 112: 527-